GTF2H5 Identified as a crucial synthetic lethal target to counteract chemoresistance in colorectal cancer

IF 5 2区 医学 Q2 Medicine
Junjie Nie , Xinwei Liu , Mu Xu , Xiaoxiang Chen , Shangshang Hu , Xinliang Gu , Huiling Sun , Tianyi Gao , Yuqin Pan , Shukui Wang
{"title":"GTF2H5 Identified as a crucial synthetic lethal target to counteract chemoresistance in colorectal cancer","authors":"Junjie Nie ,&nbsp;Xinwei Liu ,&nbsp;Mu Xu ,&nbsp;Xiaoxiang Chen ,&nbsp;Shangshang Hu ,&nbsp;Xinliang Gu ,&nbsp;Huiling Sun ,&nbsp;Tianyi Gao ,&nbsp;Yuqin Pan ,&nbsp;Shukui Wang","doi":"10.1016/j.tranon.2024.102097","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Synthetic lethality (SL) emerges as a novel concept being explored to combat cancer progression and resistance to conventional therapy. Despite the efficacy of chemotherapy in select cases of colorectal cancer (CRC), a substantial proportion of patients encounter challenges, leading to an adverse prognosis of CRC patients. CRC-related SL genes offer a potential avenue for identifying therapeutic targets.</p></div><div><h3>Methods</h3><p>CRC-related SL genes were obtained from the SynLethDB database. The bulk RNA sequencing data, mutation data, and clinical information for treated and untreated CRC patients were enrolled from the UCSC and GEO databases. The Tumor Immunology Single Cell Center database served as the repository for collecting and analyzing single-cell RNA sequencing data. The synergistic killing effect of SL genes and chemotherapeutic drugs on resistant cells was experimentally verified.</p></div><div><h3>Results</h3><p>In the present study, pivotal SL genes associated with chemoresistance identified by using WGCNA and CRC patients categorized into two groups based on these genes. Variations between the groups were most pronounced in pathways associated with extracellular matrix remodeling. Further by integrating mutation data, five potential SL genes were discerned, which were highly expressed in the presence of TP53 or KRAS mutations, leading to a severely poor prognosis. Subsequent time series analysis revealed that the expression of GTF2H5 was gradually elevated at different stages of the transition from sensitive to resistant in CRC cells. Finally, it was preliminarily verified by experiments that GTF2H5 may play a key role in driving the drug-resistant transition within CRC cells.</p></div><div><h3>Conclusions</h3><p>The identification of SL genes that collaboratively interact with chemotherapeutic agents could provide new insights into solving the issue of chemotherapy resistance in CRC patients. And GTF2H5 wields a fundamental influence in inducing chemoresistance in CRC, which provided a potential therapeutic target for CRC.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"49 ","pages":"Article 102097"},"PeriodicalIF":5.0000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002249/pdfft?md5=237ce71eb6d2bcb8d019aea27a8c26ea&pid=1-s2.0-S1936523324002249-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002249","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Synthetic lethality (SL) emerges as a novel concept being explored to combat cancer progression and resistance to conventional therapy. Despite the efficacy of chemotherapy in select cases of colorectal cancer (CRC), a substantial proportion of patients encounter challenges, leading to an adverse prognosis of CRC patients. CRC-related SL genes offer a potential avenue for identifying therapeutic targets.

Methods

CRC-related SL genes were obtained from the SynLethDB database. The bulk RNA sequencing data, mutation data, and clinical information for treated and untreated CRC patients were enrolled from the UCSC and GEO databases. The Tumor Immunology Single Cell Center database served as the repository for collecting and analyzing single-cell RNA sequencing data. The synergistic killing effect of SL genes and chemotherapeutic drugs on resistant cells was experimentally verified.

Results

In the present study, pivotal SL genes associated with chemoresistance identified by using WGCNA and CRC patients categorized into two groups based on these genes. Variations between the groups were most pronounced in pathways associated with extracellular matrix remodeling. Further by integrating mutation data, five potential SL genes were discerned, which were highly expressed in the presence of TP53 or KRAS mutations, leading to a severely poor prognosis. Subsequent time series analysis revealed that the expression of GTF2H5 was gradually elevated at different stages of the transition from sensitive to resistant in CRC cells. Finally, it was preliminarily verified by experiments that GTF2H5 may play a key role in driving the drug-resistant transition within CRC cells.

Conclusions

The identification of SL genes that collaboratively interact with chemotherapeutic agents could provide new insights into solving the issue of chemotherapy resistance in CRC patients. And GTF2H5 wields a fundamental influence in inducing chemoresistance in CRC, which provided a potential therapeutic target for CRC.

GTF2H5 被确定为对抗结直肠癌化疗耐药性的关键合成致死靶点
背景合成致死(Synthetic lethality,SL)作为一种新概念,正在被用来对抗癌症进展和传统疗法的抗药性。尽管化疗在部分结直肠癌(CRC)病例中疗效显著,但仍有相当一部分患者面临挑战,导致 CRC 患者预后不良。与 CRC 相关的 SL 基因为确定治疗靶点提供了潜在的途径。大量 RNA 测序数据、突变数据以及治疗和未治疗 CRC 患者的临床信息均来自 UCSC 和 GEO 数据库。肿瘤免疫学单细胞中心数据库是收集和分析单细胞RNA测序数据的资料库。结果在本研究中,利用 WGCNA 鉴定出了与化疗耐药性相关的关键 SL 基因,并根据这些基因将 CRC 患者分为两组。组间差异最明显的是与细胞外基质重塑相关的通路。此外,通过整合突变数据,还发现了五个潜在的 SL 基因,这些基因在 TP53 或 KRAS 基因突变时高度表达,导致严重的不良预后。随后的时间序列分析表明,在 CRC 细胞从敏感向耐药过渡的不同阶段,GTF2H5 的表达逐渐升高。最后,实验初步验证了 GTF2H5 可能在驱动 CRC 细胞耐药转变的过程中发挥了关键作用。而GTF2H5在诱导CRC化疗耐药性方面具有根本性的影响,这为CRC提供了一个潜在的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
2.00%
发文量
314
审稿时长
54 days
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信